SEARCH

SEARCH BY CITATION

References

  • 1
    Sloan-Lancaster J & Allen P M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14: 127.
  • 2
    Oldstone M B. Molecular mimicry and immune-mediated diseases. FASEB J 1998; 12: 12551265.
  • 3
    Wucherpfennig K W & Strominger J L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695705.
  • 4
    Gross D M, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703706.
  • 5
    Zhao Z S, Granucci F, Yeh L, Schaffer P A, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998; 279: 13441347.DOI: 10.1126/science.279.5355.1344
  • 6
    Bogdanos D P, Mieli-Vergani G, Vergani D. Virus, liver and autoimmunity. Dig Liver Dis 2000; 32: 440446.
  • 7
    Homberg J C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of ‘autoimmune’ hepatitis. Hepatology 1987; 7: 13331339.
  • 8
    Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988; 168: 801806.
  • 9
    Muratori L, Parola M, Ripalti A, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000; 46: 553561.
  • 10
    Vergani D. LKM antibody: getting in some target practice. Gut 2000; 46: 44950.
  • 11
    Lenzi M, Ballardini G, Fusconi M, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990; 335: 258259.
  • 12
    Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199203.
  • 13
    Vergani D & Mieli-Vergani G. Type II autoimmune hepatitis. What is the role of the hepatitis C virus?Gastroenterology 1993; 104: 18701873.
  • 14
    Yamamoto A M, Cresteil D, Boniface O, Clerc F F, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 11051111.
  • 15
    Kerkar N, Mahmoud A, Muratori L, et al. New viral triggers of autoreactivity to cytochrome P4502D6, the target of liver kidney microsomal autoantibody. J Hepatol 1999: 30 (suppl. 1): 58.
  • 16
    Klein R, Zanger U M, Berg T, Hopf U, Berg P A. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol 1999; 118: 290297.DOI: 10.1046/j.1365-2249.1999.01027.x
  • 17
    Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1991; 88: 13701378.
  • 18
    Bogdanos D P, Lenzi M, Okamoto M, et al. Generation of liver/kidney microsomal-1 antibody in HCV infection the role of molecular mimicry. J Hepatol 2000: 32 (suppl. 2): 92.DOI: 10.1016/s0168-8278(00)80194-4
  • 19
    Galvin J E, Hemric M E, Ward K, Cunningham M W. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000; 106: 217224.
  • 20
    Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, Kalil J. Autoimmunity in Chagas’ disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas’ cardiomyopathy patient. J Clin Invest 1996; 98: 17091712.
  • 21
    Gregorio G V, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541547.
  • 22
    Choudhuri K, Gregorio G V, Mieli-Vergani G, Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology 1998; 28: 11771781.
  • 23
    Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 18291836.
  • 24
    Nagamine K, Peterson P, Scott H S, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17: 393398.
  • 25
    Heino M, Peterson P, Kudoh J, et al. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem Biophys Res Commun 1999; 257: 821825.DOI: 10.1006/bbrc.1999.0308
  • 26
    Kaplan M M. Primary biliary cirrhosis. N Engl J Med 1996; 335: 15701580.
  • 27
    Bassendine M F, Jones D E, Yeaman S J. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 4960.
  • 28
    Burroughs A K, Butler P, Sternberg M J, Baum H. Molecular mimicry in liver disease. Nature 1992; 358: 377378.
  • 29
    Burroughs A K, Rosenstein I J, Epstein O, Hamilton-Miller J M, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25: 133137.
  • 30
    Vilagut L, Vila J, Vinas O, et al. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 1994; 21: 673677.
  • 31
    Parikh-Patel A, Gold E B, Worman H, Krivy K E, Gershwin M E. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001; 33: 1621.DOI: 10.1053/jhep.2001.21165
  • 32
    Hopf U, Moller B, Stemerowicz R, et al. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989; 2: 14191422.
  • 33
    Butler P, Valle F, Hamilton-Miller J M, Brumfitt W, Baum H, Burroughs A K. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993; 17: 408414.
  • 34
    Mayo I, Arizti P, Parés A, et al. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. J Hepatol 2000; 33: 528536.DOI: 10.1016/s0168-8278(00)80003-3
  • 35
    Baum H, Bogdanos D P, Vergani D. Antibodies to Clp protease in primary biliary cirrhosis: possible role of a mimicking T-cell epitope. J Hepatol 2001; 34: 785787.DOI: 10.1016/s0168-8278(01)00059-9
  • 36
    Bogdanos D P, Grasso A, Okamoto M, et al. Double reactivity to E. coli/pyruvate dehydrogenase complex-E2 characterises primary biliary cirrhosis. J Hepatol 2000: 32 (suppl 2): 39.
  • 37
    Wang J, Hartling J A, Flanagan J M. The structure of ClpP at 2.3 A resolution suggests a model for ATP-dependent proteolysis. Cell 1997; 91: 447456.
  • 38
    Gregorio G V, Jones H, Choudhuri K, et al. Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alpha. Hepatology 1996; 24: 520523.
  • 39
    Chisari F V & Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 2960.
  • 40
    Gregorio GV, Choudhuri K, Ma Y, Vegnente A, Mieli-Vergani G, Vergani D. Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol 1999; 162: 18021810.
  • 41
    Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45: 435441.
  • 42
    Deutsch M, Dourakis S, Manesis E K, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206210.
  • 43
    Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 14451448.
  • 44
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (suppl 1): 11221.
  • 45
    Dumoulin F L, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999; 53: 242254.DOI: 10.1016/s0753-3322(99)80095-x
  • 46
    McLachlan S M & Rapoport B. The molecular biology of thyroid peroxidase: cloning, expression and role as autoantigen in autoimmune thyroid disease. Endocr Rev 1992; 13: 192206.
  • 47
    Khoury E L, Hammond L, Bottazzo G F, Doniach D. Presence of the organ-specific ‘microsomal’ autoantigen on the surface of human thyroid cells in cultureits involvement in complement-mediated cytotoxicity. Clin Exp Immunol 1981; 45: 316.
  • 48
    Bogdanos D P, Lenzi M, Ma Y, et al. Treatment with interferon-alpha unmasks cross-reactive immunity between hepatitis C virus and thyroid peroxidase, the major target antigen in thyroid autoimmunity [abstract]. Hepatology 1999; 30: 363.
  • 49
    Bogdanos D P, Lenzi M, Okamoto M, et al. Thyroid peroxidase is a molecular mimicry target of anti-hepatitis C virus humoral response. J Hepatol 2000: 32 (suppl 2): 103.
  • 50
    Fujinami R S & Oldstone M B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985; 230: 10431045.